Novartis Looks To Recent Launches To Bolster Diovan Against Generic Onslaught
The Swiss pharma predicts hypertension blockbuster still will earn $2 billion annually outside the U.S. after patent expirations.
The Swiss pharma predicts hypertension blockbuster still will earn $2 billion annually outside the U.S. after patent expirations.